1. Home
  2. GANX vs OPAL Comparison

GANX vs OPAL Comparison

Compare GANX & OPAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • OPAL
  • Stock Information
  • Founded
  • GANX 2017
  • OPAL 1998
  • Country
  • GANX United States
  • OPAL United States
  • Employees
  • GANX 25
  • OPAL N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • OPAL Natural Gas Distribution
  • Sector
  • GANX Health Care
  • OPAL Utilities
  • Exchange
  • GANX Nasdaq
  • OPAL Nasdaq
  • Market Cap
  • GANX 79.8M
  • OPAL 66.1M
  • IPO Year
  • GANX 2021
  • OPAL N/A
  • Fundamental
  • Price
  • GANX $2.02
  • OPAL $2.39
  • Analyst Decision
  • GANX Strong Buy
  • OPAL Sell
  • Analyst Count
  • GANX 6
  • OPAL 4
  • Target Price
  • GANX $8.00
  • OPAL $2.81
  • AVG Volume (30 Days)
  • GANX 779.8K
  • OPAL 371.0K
  • Earning Date
  • GANX 11-13-2025
  • OPAL 11-06-2025
  • Dividend Yield
  • GANX N/A
  • OPAL N/A
  • EPS Growth
  • GANX N/A
  • OPAL N/A
  • EPS
  • GANX N/A
  • OPAL 0.06
  • Revenue
  • GANX N/A
  • OPAL $329,933,000.00
  • Revenue This Year
  • GANX N/A
  • OPAL $20.71
  • Revenue Next Year
  • GANX N/A
  • OPAL $19.52
  • P/E Ratio
  • GANX N/A
  • OPAL $41.82
  • Revenue Growth
  • GANX N/A
  • OPAL 12.22
  • 52 Week Low
  • GANX $1.41
  • OPAL $1.26
  • 52 Week High
  • GANX $3.19
  • OPAL $4.11
  • Technical
  • Relative Strength Index (RSI)
  • GANX 58.27
  • OPAL 51.21
  • Support Level
  • GANX $1.74
  • OPAL $2.25
  • Resistance Level
  • GANX $2.40
  • OPAL $2.55
  • Average True Range (ATR)
  • GANX 0.18
  • OPAL 0.22
  • MACD
  • GANX 0.04
  • OPAL 0.01
  • Stochastic Oscillator
  • GANX 49.72
  • OPAL 54.20

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About OPAL OPAL Fuels Inc.

OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.

Share on Social Networks: